Trade Alert: President Of Soleno Therapeutics Anish Bhatnagar Has Sold Stock

Some Soleno Therapeutics, Inc. (NASDAQ:SLNO) shareholders may be a little concerned to see that the President, Anish Bhatnagar, recently sold a substantial US$785k worth of stock at a price of US$41.34 per share. That's a big disposal, and it decreased their holding size by 32%, which is notable but not too bad.

Check out our latest analysis for Soleno Therapeutics

The Last 12 Months Of Insider Transactions At Soleno Therapeutics

Notably, that recent sale by President Anish Bhatnagar was not the only time they sold Soleno Therapeutics shares this year. Earlier in the year, they fetched US$37.01 per share in a -US$3.3m sale. So it's clear an insider wanted to take some cash off the table, even below the current price of US$41.80. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. We note that the biggest single sale was 84% of Anish Bhatnagar's holding.

In the last year Soleno Therapeutics insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of Soleno Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. From our data, it seems that Soleno Therapeutics insiders own 0.7% of the company, worth about US$8.9m. We do generally prefer see higher levels of insider ownership.

What Might The Insider Transactions At Soleno Therapeutics Tell Us?

Insiders haven't bought Soleno Therapeutics stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 3 warning signs for Soleno Therapeutics you should be aware of, and 2 of these are a bit concerning.

Of course Soleno Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.